At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
In Brief
A Phase 2 clinical trial evaluating GDC-6599, GDC-6599-matching placebo, and 1 other intervention for Chronic Refractory Cough (CRC) With Non-atopic Asthma and 4 related conditions. Completed, enrolled 49 participants across 18 sites in 4 countries.
Detailed Summary
This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with a history of chronic cough.
Study Details
Timeline
Interventions
GDC-6599 will be administered Days 1- 14 and on Days 29-42 as film-coated tablets
GDC-6599-matching placebo will be administered Days 1- 14 and on Days 29- 42. as film-coated tablets
Mannitol challenge tests will be performed during screening and at least 2.5 hours following study drug administration at Study Visits 2, 4, 5 and 7